Jun 16, 2025

Major Depressive Disorder Recurrent (F33) - ICD-10 Guide for Clinicians Guide for Mental Health Professionals

Brayden Efseroff, MD

Allia Team

A comprehensive ICD-10 guide for mental health professionals on Major Depressive Disorder, Recurrent (F33). Includes diagnostic criteria, coding, assessment tools, and evidence-based treatments.

Table of Contents

    Table of Contents

      Quick Reference

      Code: F33 (with 4th and 5th character specifications)
      Diagnosis: Major Depressive Disorder, Recurrent
      Category: Mood (Affective) Disorders
      Billing Status: Active code for reimbursement (requires 4th character)
      DSM-5 Equivalent: 296.3x (Major Depressive Disorder, Recurrent)
      Common Comorbidities: Anxiety Disorders, Substance Use Disorders, Personality Disorders, Chronic Pain, Cardiovascular Disease

      Clinical Description

      Major Depressive Disorder, Recurrent is characterized by two or more major depressive episodes separated by at least 2 months of remission. Each episode involves persistent depressed mood and/or loss of interest or pleasure, accompanied by additional symptoms that cause clinically significant distress or functional impairment.

      ICD-10 Coding Specifications

      F33.0 - Recurrent depressive disorder, current episode mild
      F33.1 - Recurrent depressive disorder, current episode moderate
      F33.2 - Recurrent depressive disorder, current episode severe without psychotic features
      F33.3 - Recurrent depressive disorder, current episode severe with psychotic features
      F33.4 - Recurrent depressive disorder, currently in remission
      F33.8 - Other recurrent depressive disorders
      F33.9 - Recurrent depressive disorder, unspecified

      Diagnostic Criteria

      For Major Depressive Episode:

      • Five or more of the following symptoms present during the same 2-week period (at least one must be depressed mood or loss of interest/pleasure):

        • Depressed mood most of the day, nearly every day

        • Markedly diminished interest or pleasure in activities

        • Significant weight loss/gain or appetite changes

        • Insomnia or hypersomnia nearly every day

        • Psychomotor agitation or retardation

        • Fatigue or loss of energy nearly every day

        • Feelings of worthlessness or excessive/inappropriate guilt

        • Diminished ability to think/concentrate or indecisiveness

        • Recurrent thoughts of death or suicidal ideation

      For Recurrent Specification:

      • History of at least one previous major depressive episode

      • Current episode meets criteria for major depressive episode

      • Episodes separated by at least 2 consecutive months without significant mood symptoms

      Severity Specifiers

      Severity

      Criteria

      Functional Impact

      Mild

      Few symptoms beyond minimum required; minor functional impairment

      Able to function with effort

      Moderate

      Symptoms/functional impairment between mild and severe

      Significant functional difficulties

      Severe

      Most symptoms present; marked functional impairment

      Substantial impairment in most areas

      With Psychotic Features

      Delusions or hallucinations present

      Severe impairment with reality testing issues

      Differential Diagnosis

      Condition

      Distinguishing Features

      ICD-10 Code

      Bipolar I Disorder

      History of manic episodes

      F31.x

      Bipolar II Disorder

      History of hypomanic episodes

      F31.81

      Persistent Depressive Disorder

      Chronic depression lasting 2+ years

      F34.1

      Adjustment Disorder with Depressed Mood

      Clear stressor, symptoms within 6 months

      F43.21

      Substance-Induced Mood Disorder

      Temporal relationship with substance use

      F10-F19

      Medical Condition-Related

      Due to physiological effects of medical condition

      F06.3x

      Bereavement

      Normal grief response (though can co-occur). Must not include acute safety risks or persistent decline in function.

      Z63.4

      Transdiagnostic Considerations

      MDD is part of the Internalizing disorders spectrum, sharing common symptoms and treatments with anxiety disorders and trauma-related conditions. Comorbidity rates are high, and treatment approaches often need to address multiple conditions simultaneously.

      Assessment Tools

      Validated Screening & Assessment Instruments

      Instrument

      Description

      Scoring

      PHQ-9

      9-item self-report depression screener

      0-4: Minimal

      5-9: Mild

      10-14: Moderate

      15-19: Moderately Severe

      20-27: Severe

      Beck Depression Inventory-II (BDI-II)

      21-item self-report measure

      0-13: Minimal

      14-19: Mild

      20-28: Moderate

      29-63: Severe

      Hamilton Depression Rating Scale (HAM-D)

      Clinician-administered, 17 or 21-item scale

      0-7: Normal

      8-16: Mild

      17-23: Moderate

      ≥24: Severe

      Montgomery-Åsberg Depression Rating Scale (MADRS)

      10-item clinician-rated scale

      0-6: Normal

      7-19: Mild

      20-34: Moderate

      35-60: Severe

      Geriatric Depression Scale (GDS)

      15 or 30-item yes/no format for older adults

      15-item: 0-4: Normal

      5-8: Mild

      9-11: Moderate1

      2-15: Severe

      Edinburgh Postnatal Depression Scale (EPDS)

      10-item scale for perinatal depression

      Score ≥10 indicates possible depression

      Score ≥13 indicates likely depression

      Treatment Approaches

      Evidence-Based Psychotherapy Options

      Psychotherapy is a cornerstone of depression treatment, with multiple approaches showing strong efficacy. The choice of therapy should be individualized based on patient preferences, symptom profile, and treatment history.

      Approach

      Level of Evidence

      Key Components

      Typical Duration

      Cognitive Behavioral Therapy (CBT)

      Strong

      Cognitive restructuring, behavioral activation, relapse prevention

      16-20 sessions

      Interpersonal Therapy (IPT)

      Strong

      Focus on interpersonal relationships, grief, role transitions

      12-16 sessions

      Behavioral Activation (BA)

      Strong

      Activity scheduling, mood monitoring, values-based action

      12-16 sessions

      Psychodynamic Therapy

      Moderate

      Insight-oriented, transference work, unconscious patterns

      16-30 sessions

      Dialectical Behavior Therapy (DBT)

      Moderate

      Mindfulness, distress tolerance, emotion regulation

      12-24 sessions

      Acceptance and Commitment Therapy (ACT)

      Moderate

      Psychological flexibility, values clarification, mindfulness

      12-16 sessions

      Evidence-Based Medication Options

      Antidepressant medications are highly effective for moderate to severe depression. Treatment selection should consider symptom profile, side effect tolerance, drug interactions, and patient preferences.

      Medication Class

      First-Line Options

      Starting Dose

      Target Dose

      Notes

      SSRIs

      Sertraline

      Escitalopram

      Fluoxetine

      Citalopram

      25-50 mg/day

      5-10 mg/day

      10-20 mg/day

      10-20 mg/day

      50-200 mg/day

      10-20 mg/day

      20-80 mg/day

      20-40 mg/day

      Generally well-tolerated, sexual side effects common

      SNRIs

      Venlafaxine XR

      Duloxetine

      Desvenlafaxine

      37.5-75 mg/day

      30-60 mg/day

      50 mg/day

      75-300 mg/day

      60-120 mg/day

      50-100 mg/day

      Monitor blood pressure, discontinuation syndrome

      Atypical Antidepressants

      Bupropion XL

      Mirtazapine

      Vortioxetine

      150 mg/day

      15 mg/day

      5-10 mg/day

      300-450 mg/day15-45 mg/day10-20 mg/day

      Bupropion: seizure risk, weight loss

      Mirtazapine: sedation, weight gain

      Tricyclics

      Nortriptyline

      Amitriptyline

      25 mg/day

      25 mg/day

      75-150 mg/day75-300 mg/day

      Cardiac monitoring, anticholinergic effects

      Treatment-Resistant Depression Options

      Intervention

      Evidence Level

      Considerations

      Medication Augmentation

      Strong

      Lithium, thyroid hormone, antipsychotics

      Combination Therapy

      Strong

      Two antidepressants with different mechanisms

      Electroconvulsive Therapy (ECT)

      Strong

      Most effective for severe, psychotic, or catatonic depression

      Transcranial Magnetic Stimulation (TMS)

      Moderate

      FDA-approved for treatment-resistant depression

      Ketamine/Esketamine

      Moderate

      Rapid-acting, FDA-approved for treatment-resistant depression

      Vagus Nerve Stimulation (VNS)

      Emerging

      For chronic, treatment-resistant cases

      Integrative Treatment Considerations

      • Exercise: Moderate aerobic exercise (30+ minutes, 3-5 times/week) shows efficacy comparable to medication

      • Sleep interventions: CBT for insomnia, sleep hygiene, addressing sleep disorders

      • Nutritional factors: Mediterranean diet, omega-3 fatty acids, vitamin D supplementation

      • Light therapy: Particularly effective for seasonal patterns

      • Mindfulness-based interventions: MBSR, MBCT for relapse prevention

      • Social support: Group therapy, peer support, family involvement

      Addressing Common Treatment Challenges

      Challenge

      Strategies

      Medication non-adherence

      Psychoeducation, simplified dosing, side effect management

      Suicidal ideation

      Safety planning, crisis contacts, family involvement

      Cognitive symptoms

      Cognitive rehabilitation, medication optimization

      Chronic pain comorbidity

      Integrated pain management, SNRIs, tricyclics

      Substance use comorbidity

      Integrated treatment, motivational interviewing

      Antidepressant resistance

      Medication augmentation, combination therapy, ECT

      Documentation, Coding, and Reimbursement

      ICD-10 Coding Tips

      • F33 requires a 4th character to specify current episode severity

      • 5th character may be used for additional specifications (e.g., F33.10 for mild episode without somatic syndrome)

      • Document episode count and duration of remission periods

      • Specify psychotic features when present (F33.3)

      • Use F33.4 for patients currently in remission

      • Can be used as primary or secondary diagnosis

      Medical Necessity Documentation Language

      Example statements to support medical necessity:

      • "Patient exhibits significant functional impairment in [specific domains] as evidenced by [specific examples]"

      • "Current major depressive episode represents [#] recurrence, with previous episodes occurring in [timeframe]"

      • "PHQ-9 score of [X] indicates [severity level] depression requiring professional intervention"

      • "Patient reports [specific symptoms] occurring daily for [duration] weeks"

      • "Suicidal ideation present with [frequency/intensity] requiring immediate intervention"

      Other Documentation Requirements for Reimbursement

      • Documented evidence of at least 5 depressive symptoms

      • Duration criteria (2+ weeks) explicitly stated

      • Previous episode history documented

      • Functional impairment specified with examples

      • Suicide risk assessment documented

      • Differential diagnosis considered and ruled out

      • Treatment plan with specific, measurable goals

      Specific Payer Considerations

      Payer

      Typical Reimbursement

      Authorization Requirements

      Session Limits

      Medicare

      Covered under Part B

      No prior auth for outpatient

      No specific limit

      Medicaid

      Varies by state

      Often requires auth after 10-12 sessions

      Varies by state

      BCBS

      Covered

      May require auth after 12-16 sessions

      Varies by plan

      Aetna

      Covered

      Some plans require auth

      Often 26 sessions/year

      UnitedHealthcare

      Covered

      Some plans require auth

      Varies by plan

      Client Education Resources

      Handouts for Clients

      Digital Resources

      • Recommended Apps:

        • Moodtools: CBT-based depression management

        • Sanvello: Mood tracking and coping skills

        • Headspace: Meditation and mindfulness

        • Daylio: Mood and activity tracking

      • Online Communities: 

        • NAMI (national alliance on mental illness)

        • Depression and Bipolar Support Alliance (DBSA) online support groups

      Psychoeducational Talking Points

      • The neurobiological basis of depression: Depression involves changes in brain neurotransmitters (serotonin, norepinephrine, dopamine) and neural circuits, particularly those involved in mood regulation, reward processing, and stress response. These biological changes explain why depression isn't simply "feeling sad" but involves physical symptoms like fatigue, sleep disturbances, and concentration difficulties. Understanding the brain basis helps reduce self-blame and stigma while supporting the rationale for both medication and therapy, as treatments work by helping restore healthy brain function through different but complementary mechanisms.

      • The relationship between thoughts, mood, and behavior: Depression creates a negative cycle where pessimistic thoughts fuel depressed mood, which leads to withdrawal and inactivity, which then generates more negative thoughts about being "lazy" or "worthless." This cycle is self-reinforcing because depression affects our ability to think clearly and remember positive experiences. Breaking this cycle requires intervening at multiple points: challenging negative thought patterns, gradually increasing meaningful activities, and improving physical health through sleep, exercise, and nutrition.

      • Depression as a treatable medical condition: Depression is a legitimate medical illness with biological, psychological, and social components. Like diabetes or heart disease, it requires proper treatment and management. Recovery is possible with appropriate treatment, though it may take time to find the right combination of approaches. The recurrent nature of depression means that learning long-term management strategies is crucial, similar to managing other chronic conditions.

      • The importance of behavioral activation: When depressed, people naturally withdraw from activities, which temporarily reduces stress but ultimately worsens depression by eliminating sources of pleasure, accomplishment, and social connection. Behavioral activation involves gradually re-engaging with meaningful activities, even when motivation is low. Starting with small, achievable tasks helps rebuild confidence and energy. The key is that behavior change often precedes mood improvement, so patients shouldn't wait to "feel better" before becoming active.

      • Recognizing early warning signs and relapse prevention: Since depression is often recurrent, learning to identify personal early warning signs is crucial for preventing full episodes. These might include sleep changes, increased irritability, social withdrawal, or negative thinking patterns. Developing a relapse prevention plan includes maintaining healthy routines, staying connected with support systems, continuing beneficial activities, and seeking help promptly when warning signs appear. Many people benefit from "maintenance" therapy sessions to monitor symptoms and maintain coping skills.

      Reference Materials and Further Reading

      Clinical Practice Guidelines

      Emerging Research

      Precision medicine approaches for depression treatment selection

      Chekroud AM, Bondar J, Delgadillo J, et al. The promise of machine learning in predicting treatment outcomes in psychiatry. World Psychiatry. 2021 Jun;20(2):154-170.

      Digital therapeutics and smartphone-based interventions

      Linardon J, Cuijpers P, Carlbring P, Messer M, Fuller-Tyszkiewicz M. The efficacy of app-supported smartphone interventions for mental health problems: a meta-analysis of randomized controlled trials. World Psychiatry. 2019 Oct;18(3):325-336.

      Inflammation and depression: novel treatment targets
      Köhler-Forsberg O, N Lydholm C, Hjorthøj C, et al. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019 Oct;140(4):266-281.

      Personalized neurostimulation approaches
      Siddiqi SH, Weigand A, Pascual-Leone A, Fox MD. Identification of personalized transcranial magnetic stimulation targets based on subgenual cingulate connectivity: An independent replication. Biol Psychiatry. 2021 Jan 15;89(2):e55-e57.

      Specialized Books for Clinicians

      "Cognitive Therapy of Depression" by Aaron T. Beck, A. John Rush, Brian F. Shaw, and Gary Emery

      This seminal work established the foundation for cognitive therapy of depression and remains the gold standard reference. It provides detailed treatment protocols, case examples, and the theoretical framework for understanding depression from a cognitive perspective. Essential for any clinician using CBT approaches with depressed patients.

      "Interpersonal Psychotherapy of Depression: A Brief, Focused, Specific Strategy" by Gerald L. Klerman and Myrna M. Weissman

      The definitive guide to IPT, this book provides structured treatment protocols focusing on interpersonal relationships and their role in depression. It offers practical session-by-session guidance and is particularly valuable for clinicians treating depression with relationship and social functioning components.

      "Behavioral Activation for Depression: A Clinician's Guide" by Christopher R. Martell, Sona Dimidjian, and Ruth Herman-Dunn

      This comprehensive guide presents behavioral activation as a standalone treatment for depression. It provides detailed protocols, case examples, and practical strategies for helping clients re-engage with meaningful activities and break the cycle of depression and withdrawal.

      "Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse" by Zindel V. Segal, J. Mark G. Williams, and John D. Teasdale

      This book presents MBCT as an evidence-based approach for preventing depressive relapse. It provides detailed protocols combining mindfulness practices with cognitive therapy techniques, particularly valuable for clients with recurrent depression.

      Last Updated: June 2025

      About This Resource: This comprehensive guide was developed to support mental health professionals in providing evidence-based assessment and treatment for clients with Major Depressive Disorder. While efforts have been made to ensure accuracy, clinicians should refer to current DSM-5 and ICD-10 manuals for official diagnostic criteria and stay informed about evolving best practices.